摘要
含Jumonji结构域-3(jumonji domain containing-3, JMJD3)的组蛋白去甲基化酶又称赖氨酸去甲基酶6B(lysine demethylase 6B, KDM6B),属于组蛋白H3赖氨酸27(H3K27)去甲基酶的KDM6家族,后者也包括UTX(KDM6A)和JMJD3(KDM6B)。目前越来越多的研究表明,JMJD3的失调与各种癌症的发生密切相关,靶向JMJD3在不同类型的癌症中具有显著的治疗潜力。为此,笔者将对JMJD3在癌症中的功能作简要综述,探讨JMJD3调控肿瘤发生的信号机制,并对现有的针对JMJD3的化合物和药物进行评价。
The Jumonji domain containing-3(JMJD3), also known as lysine demethylase 6 B(KDM6 B), belongs to the KDM6 family of histone H3 lysine 27(H3 K27) demethylases, which also includes UTX(KDM6 A) and JMJD3(KDM6 B). Previous studies have shown that dysregulation of JMJD3 is closely linked to tumorigenesis in various cancers. Accumulating evidence suggested that there is remarkable therapeutic potential for targeting JMJD3 in different types of cancer. Herein, we are gaved a brief review on the functional roles of JMJD3 in cancers, examined how JMJD3 regulates cancer cells, and evaluated the available compounds and agents targeting JMJD3.
作者
杜建波
王玉敏
DU Jian-bo;WANG Yu-min(Department of General Surgery,The Affiliated Hospital of Chifeng University,Chifeng024000,China;Department of Respiratory and Critical Care Medicine,Aerospace Center Hospital,Peking University Aerospace School of Clini-cal Medicine,Beijing100049,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2022年第4期258-263,共6页
Chinese Pharmaceutical Journal
基金
内蒙古自然科学基金项目资助(2020MS09715,2021MS08131,2021LHMS08024)
内蒙古自治区高等学校青年科技英才支持计划资助(NJYT-17-B23)
“草原英才”工程计资助(CYYC8107)
航天中心医院院级课题资助(YN202104)
中国航天科工集团课题资助(2020-LCYL-009)
北京市海淀区卫生健康发展科研培育计划资助(HP2021-19-50701)。
